Scientific investigations sometimes result in serendipitous discoveries which shift the investigations from one focus to another. In the case of researchers at Mayo Clinic in Arizona, studies addressing obesity’s impact on cancer treatment resulted in an unexpected discovery that shifted the focus from cancer to obesity. The investigators observed that two common cancer-fighting drugs sparked significant weight loss in the obese mice, even though the mice continued their excessive consumption of a high-fat diet.
These results, which are part of a Mayo Clinic study, were reported in the Jan. 17 edition of Oncotarget.
“We were surprised to observe that when morbidly obese mice were treated with certain cancer-fighting drugs, the drugs not only targeted their cancers, but also tended to spontaneously resolve their obesity ? even with undiminished gorging on a high-fat diet,” says Mayo Clinic cancer immunotherapist Peter Cohen, M.D., who co-led the study with postdoctoral fellow Cheryl Myers, Ph.D. and Mayo Clinic immunologist Sandra Gendler, Ph.D.
“Importantly, two chemotherapy agents ? methotrexate and cyclophosphamide ? could be dosed to completely reverse obesity without detectable toxicity, even in mice without cancer,” explains Dr. Myers. “Interestingly, these drugs are already used to treat some noncancerous conditions, such as rheumatoid arthritis.”
More research needs to be done to see if the same outcome can be achieved in morbidly obese patients.
“The ease with which this weight loss was achieved in mice ? even with continued caloric binging ? is in stark contrast to the Herculean difficulties morbidly obese patients experience trying to preserve weight loss through dietary restraint,” adds Dr. Gendler.
The weight reduction observed in the obese mice was not attributable to trivial explanations, such as a decrease in dietary intake, increased energy expenditure or malabsorption. Instead, the investigators identified multiple effects of methotrexate or cyclophosphamide that worked together to expedite loss of excessive weight in mice. Much like chemotherapy’s well-known ability to decrease red and white blood cell precursors transiently, methotrexate or cyclophosphamide depleted fat cell precursors, leading to much decreased fat storage. “This meant that excessive dietary calories had to go somewhere else in the body instead, such as to the liver,” explains Dr. Cohen.
“Surprisingly, the liver maintained a robust level of metabolic activity during methotrexate or cyclophosphamide treatment, but was nearly shut down in regards to fat production and fat storage,” adds Dr. Myers.
“Based on our composite data,” explains Dr. Gendler, “it appears that methotrexate or cyclophosphamide can induce the livers of obese mice to burn off rather than accumulate excessive dietary fat. This results in desirable weight reduction instead of increased obesity, even with continued caloric binging.”
The study sets the stage for further research, exploring how these metabolic mechanisms could reduce the need for severe dietary constraints in morbidly obese individuals.
Receive an email update when we add a new WEIGHT LOSS article.
The Latest on: Methotrexate and cyclophosphamide
via Google News
The Latest on: Methotrexate and cyclophosphamide
- Treatments for Gestational Trophoblastic Diseaseon May 22, 2020 at 5:00 pm
CO: Cyclophosphamide and vincristine; EMA: Etoposide, methotrexate and actinomycin D; iv.: Intravenous. 1 Paclitaxel 135 mg/m 2 by iv. infusion over 3 h Cisplatin 60 mg/m 2 iv. infusion over 3 h ...
- Systemic Lupus Erythematosus Treatment Market is Projected to Expand at a CAGR of ~7% from 2019 to 2027on May 22, 2020 at 7:13 am
TMR has published a new report on the systemic lupus erythematosus treatment market for the forecast period of 2019 2027 According to the report the global systemic lupus erythematosus treatment ...
- HIV-related Lymphomaon May 21, 2020 at 5:00 pm
BEMOP: Bleomycin, etoposide, vincristine, methotrexate and prednisolone; CA: Cyclophosphamide and doxorubicin; CDE: Cyclophosphamide, doxorubicin and etoposide; CHOP ...
- Rituximab versus Cyclophosphamide in ANCA-Associated Renal Vasculitison May 20, 2020 at 5:00 pm
Cyclophosphamide induction regimens for ... increase in infectious complications when used in combination with methotrexate for the treatment of rheumatoid arthritis 9 or with chemotherapy for ...
- Takeda to Present Data at Upcoming Virtual Scientific Congresses, Underscoring Breadth of Oncology Portfolio and Emerging Pipelineon May 14, 2020 at 9:17 am
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) ("Takeda") today announced that the company will present data from its expanding oncology pipeline and established product portfolio at two u ...
- Vulnerability to reservoir reseeding due to high immune activation after allogeneic hematopoietic stem cell transplantation in individuals with HIV-1on May 6, 2020 at 11:14 am
1 1. Department of Medicine, Infectious Diseases Unit, University Medical Center Hamburg Eppendorf, 20246 Hamburg, Germany. 2 DZIF Partner Site (German Center for Infection Research), ...
- 2015 ASCO Annual Meeting Ion April 25, 2020 at 4:06 pm
Kidney Injury Molecule-1 and its association with delayed clearance and drug exposure in pediatric oncology patients treated with high dose methotrexate ... A meta-analysis of randomized trials ...
- B-Cell Acute Lymphoblastic Leukemia: Adding Inotuzumab Ozogamicin to Chemotherapyon February 29, 2020 at 11:20 am
Inotuzumab ozogamicin is a monoclonal antibody, called inotuzumab, linked to a type of chemotherapy called calicheamicin. Inotuzumab attaches to cancer cells in a targeted way and delivers ...
- The convergence of clinical research and clinical careon April 10, 2019 at 4:54 pm
A striking change in the field of rheumatology has been highlighted ... hydroxychloroquine, methotrexate, and cyclophosphamide in these diseases is also unknown. As a result, laborious pragmatic ...
via Bing News